Somerville Development Partners

Somerville Development Partners is a specialized regulatory affairs consultancy serving the biotech and pharma sectors, with a core focus on oncology, hematology, ophthalmology, rare diseases, and cell & gene therapies. The firm offers end-to-end pre-approval regulatory services, including strategic planning, scientific advice, orphan designations, and marketing authorization applications, acting as an integrated extension of its clients' teams. As a registered SME with the EMA, it provides significant value to emerging companies by facilitating access to regulatory fee reductions and advanced support. The company is privately held, operates on a fee-for-service business model, and is led by a small team of seasoned regulatory professionals.

Integrated regulatory affairs consultancy service model leveraging data-driven strategy, deep regulatory science expertise, and registered SME status with the EMA to guide clients from early development to market authorization.

Competes with large global Contract Research Organizations (CROs) offering regulatory services, other boutique regulatory consultancies, and independent consultants. Differentiation is achieved through a dedicated SME focus, senior-level hands-on service, and the strategic advantage of holding an EMA-registered SME status on behalf of clients.